Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Mini GPS in a needle could help doctors hit hidden tumors

NCT ID NCT00102544

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 6 times

Summary

This study tests a special needle with a tiny tracking device inside, like a mini GPS, to help doctors find tumors that are hard to see on CT scans. About 3,900 adults with certain cancers or growths will have their biopsy or ablation procedure done using this smart needle. The goal is to see if the system can accurately guide the needle to the right spot, potentially making these procedures more precise.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Electromagnetic tracking device (GPS-like needle guidance system)
What this could lead to
If successful, this technology could make biopsies and tumor ablations more accurate and safer by helping doctors precisely target hard-to-see lesions.
What could go wrong
This is an early feasibility study focused on accuracy, not treatment outcomes. The device may not improve success rates or reduce complications in real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3,894 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2005

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: Patients must fulfill all of the following criteria to be eligible for study admission. Patient enrollment is by referral only. 1. All patients must have a pre-operative imaging (CT, MR, or PET scan) available in digital format. 2. Age greater than or equal to 18 years. 3. No serious concurrent medical illness that would preclude the patient from making a rational informed decision on participation. 4. The ability to understand and willingness to sign a written informed consent form, and to comply with the protocol. If in question, an ethics consult will be obtained. 5. All patients in non-prostate biopsy cohorts, must be undergoing an image-guided surgical or interventional radiology procedure such as an angiography or a CT/ US-guided biopsy as clinically indicated or IRB-approved under a separate research protocol. PROSTATE BIOPSY COHORT (Cohorts 1 and 9) INCLUSION CRITERIA: 1\. Patients are eligible if they have undergone a prostate MRI and have had abnormalities identified as follows: 1. PSA \>2.5 OR abnormal digital rectal exam OR an abnormality identified on prostate MRI with a clinical indication for fusion biopsy 2. Pre-biopsy prostate MRI showing targetable lesions EXCLUSION CRITERIA: Patients with any of the following will be excluded from study entry: 1. Patients with an altered mental status that precludes understanding or consenting for the biopsy procedure will be excluded from this study. 2. Patients unlikely able to hold reasonably still on a procedure table for the length of the procedure. 3. Inability to hold breath, if procedure will be performed with conscious sedation, and without general anesthesia. 4. Patients with pacemakers and other potentially electrically conductive implants. 5. Gross body weight above the CT table limit (606 pounds), if CT table used.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.